Advertisement

Future Goals for Therapeutic Monoclonal Antibodies

  • Lucienne Chatenoud
  • Michelle Webb
  • Jean-François Bach
Part of the Medical Intelligence Unit book series (MIU.LANDES)

Abstract

Fifteen years of experience in using immunosuppressive monoclonal antibodies for studies predominantly in experimental and clinical transplantation, but also in autoimmunity, has clearly demonstrated the existence of therapeutic activities not shared by conventional chemical immunosuppressants (i.e. corticosteroids, azathioprine, cyclosporine, FK506). Antibodies to CD3 (OKT3) have been remarkably efficacious in reversing severe acute allograft rejection, a clinical situation in which only high-dose steroids and polyclonal antilymphocyte antibodies have similar efficacy.1–3 More importantly, antibodies or genetically engineered molecules to distinct T-cell receptors (CD4, CD4+CD8, CD28/CTLA4Ig, adhesion receptors or adhesins) can promote tolerance, namely, a stable and antigen-specific state of immunological unresponsiveness.4 As a result, a wide variety of experimental situations have been described where T cell-directed monoclonal antibodies have afforded tolerance not only to foreign soluble antigens but also to tissue alloantigens and autoantigens.5–16 Thus, despite the different problems surrounding their production and clinical development, i.e. high cost and side effects (namely, acute cytokine-related syndrome, xenosensitization), continued effort in pursuing the study of therapeutic monoclonals appears worthwhile.

Keywords

Therapeutic Monoclonal Antibody Acute Renal Allograft Rejection Antigenic Modulation OKT3 Monoclonal Antibody Antilymphocyte Serum 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Cosimi AB, Colvin RB, Burton RC et al. Use of monoclonal antibodies to T-cell subsets for immunologic monitoring and treatment in recipients of renal allografts. N Engl J Med 1981; 305: 308–314.PubMedGoogle Scholar
  2. 2.
    Cosimi AB, Burton RC, Colvin RB et al. Treatment of acute renal allograft rejection with OKT3 monoclonal antibody. Transplantation 1981; 32: 535–539.PubMedGoogle Scholar
  3. 3.
    Ortho Multicenter Transplant Study Group. A randomized clinical trial of OKT3 monoclonal antibody for acute rejection of cadaveric renal transplants. N Engl J Med 1985; 313: 337–342.Google Scholar
  4. 4.
    Schwartz RH. Immunological tolerance. In: Fundamental Immunology, Paul WE (Ed.) 1993; 677-731.Google Scholar
  5. 5.
    Benjamin RJ, Waldmann H. Induction of tolerance by monoclonal antibody therapy. Nature 1986; 320: 449–451.PubMedGoogle Scholar
  6. 6.
    Gutstein NL, Seaman WE, Scott JH et al. Induction of immune tolerance by administration of monoclonal antibody to L3T4. J Immunol 1986; 137: 1127–1132.PubMedGoogle Scholar
  7. 7.
    Cobbold SP, Qin S, Leong LY et al. Reprogramming the immune system for peripheral tolerance with CD4 and CD8 monoclonal antibodies. Immunol Rev 1992; 129: 165–201.PubMedGoogle Scholar
  8. 8.
    Isobe M, Yagita H, Okumura K et al. Specific acceptance of cardiac allograft after treatment with antibodies to ICAM-1 and LFA-1. Science 1992; 255: 1125–1127.PubMedGoogle Scholar
  9. 9.
    Springer TA, Dustin ML, Kishimoto TK et al. The lymphocyte function-associated LFA-1, CD2, and LFA-3 molecules: cell adhesion receptors of the immune system. Annu Rev Immunol 1987; 5: 223–252.PubMedGoogle Scholar
  10. 10.
    Lin H, Bolling SF, Linsley PS et al. Long-term acceptance of major histocompatibility complex mismatched cardiac allografts induced by CTLA4Ig plus donor-specific transfusion. J Exp Med 1993; 178: 1801–1806.PubMedGoogle Scholar
  11. 11.
    Brostoff SW, Mason DW. Experimental allergic encephalomyelitis: successful treatment in vivo with a monoclonal antibody that recognizes T helper cells. J Immunol 1984; 133: 1938–1942.PubMedGoogle Scholar
  12. 12.
    Christadoss P, Dauphinee MJ. Immunotherapy for myasthenia gravis: a murine model. J Immunol 1986; 136: 2437–2440.PubMedGoogle Scholar
  13. 13.
    Wofsy D, Seaman WE. Reversal of advanced murine lupus in NZB/NZW F1 mice by treatment with monoclonal antibody to L3T4. J Immunol 1987; 138: 3247–3253.PubMedGoogle Scholar
  14. 14.
    Waldor MK, Sriram S, Hardy R et al. Reversal of experimental allergic encephalomyelitis with monoclonal antibody to a T-cell subset marker. Science 1985; 227: 415–417.PubMedGoogle Scholar
  15. 15.
    Shizuru JA, Taylor-Edwards C, Banks BA et al. Immunotherapy of the nonobese diabetic mouse: treatment with an antibody to T-helper lymphocytes. Science 1988; 240: 659–662.PubMedGoogle Scholar
  16. 16.
    Chatenoud L, Thervet E, Primo J et al. Anti-CD3 antibody induces long-term remission of overt autoimmunity in nonobese diabetic mice. Proc Natl Acad Sci USA 1994; 91: 123–127.PubMedGoogle Scholar
  17. 17.
    Schwartz RS. Autoimmunity and autoimmune diseases. In: Fundamental Immunology, Paul WE (Ed.) 1993; 1033-1097.Google Scholar
  18. 18.
    Owen RD. Immunogenetic consequences of vascular anastomoses between bovine twins. Science 1945; 102: 400–401.PubMedGoogle Scholar
  19. 19.
    Billingham RE, Brent L, Medawar PB. Actively acquired tolerance to foreign cells. Nature 1953; 172: 603–606.PubMedGoogle Scholar
  20. 20.
    Sykes M, Sachs DH. Bone marrow transplantation as a means of inducing tolerance. Semin Immunol 1990; 2: 401–417.PubMedGoogle Scholar
  21. 21.
    Roser BJ. Cellular mechanisms in neonatal and adult tolerance. Immunol Rev 1989; 107: 179–202.PubMedGoogle Scholar
  22. 22.
    Heeg K, Wagner H. Analysis of immunological tolerance to major histocompatibility complex antigens. I. High frequencies of tolerogen-specific cytotoxic T lymphocyte precursors in mice neonatally tolerized to class I major histocompatibility complex antigens. Eur J Immunol 1985; 15: 25–30.PubMedGoogle Scholar
  23. 23.
    Stockinger B. Cytotoxic T-cell precursors revealed in neonatally tolerant mice. Proc Natl Acad Sci USA 1984; 81: 220–223.PubMedGoogle Scholar
  24. 24.
    Streilein JW, Gruchalla RS. Analysis of neonatally induced tolerance of H-2 alloantigens. I. Adoptive transfer indicates that tolerance of class I and class II antigens is maintained by distinct mechanisms. Immunogenetics 1981; 12: 161–173.PubMedGoogle Scholar
  25. 25.
    Nossal GJ, Pike BL. Functional clonal deletion in immunological tolerance to major histocompatibility complex antigens. Proc Natl Acad Sci USA 1981; 78: 3844–3847.PubMedGoogle Scholar
  26. 26.
    McCarthy SA, Bach FH. The cellular mechanism of maintenance of neonatally induced tolerance to H-2 class I antigens. J Immunol 1983; 131: 1676–1682.PubMedGoogle Scholar
  27. 27.
    Speiser DE, Schneider R, Hengartner H et al. Clonal deletion of self-reactive T cells in irradiation bone marrow chimeras and neonatally tolerant mice. Evidence for intercellular transfer of Mlsa. J Exp Med 1989; 170: 595–600.PubMedGoogle Scholar
  28. 28.
    Sykes M, Sheard M, Sachs DH. Effects of T cell depletion in radiation bone marrow chimeras. I. Evidence for a donor cell population which increases allogeneic chimerism but which lacks the potential to produce GVHD. J Immunol 1988; 141: 2282–2288.PubMedGoogle Scholar
  29. 29.
    Zinkernagel RM, Althage A, Callahan G et al. On the immunocompetence of H-2 incompatible irradiation bone marrow chimeras. J Immunol 1980; 124: 2356–2365.PubMedGoogle Scholar
  30. 30.
    Lapidot T, Terenzi A, Singer TS et al. Enhancement by dimethyl myleran of donor type chimerism in murine recipients of bone marrow allografts. Blood 1989; 73: 2025–2032.PubMedGoogle Scholar
  31. 31.
    Leong Ly, Qin S, Cobbold SP et al. Classical transplantation tolerance in the adult: the interaction between myeloablation and immunosuppression. Eur J Immunol 1992; 22: 2825–2830.PubMedGoogle Scholar
  32. 32.
    Deeg HJ, Storb R, Thomas ED. Bone marrow transplantation: a review of delayed complications. Br J Haematol 1984; 57: 185–208.PubMedGoogle Scholar
  33. 33.
    Monaco AP, Wood ML, Russell PS. Studies on heterologous antilymphocyte serum in mice. III. Immunological tolerance and chimerism produced across the H2-locus with adult thymectomy and antilymphocyte serum. Ann NY Acad Sci 1966; 129: 190.Google Scholar
  34. 34.
    Wood ML, Monaco AP, Gozzo JJ et al. Use of homozygous allogeneic bone marrow for induction of tolerance with antilymphocyte serum: dose and timing. Transplant Proc 1971; 3: 676–679.PubMedGoogle Scholar
  35. 35.
    Maki T, Gottschalk R, Wood ML et al. Specific unresponsiveness to skin allografts in anti-lymphocyte serum-treated, marrow-injected mice: participation of donor marrow-derived suppressor T cells. J Immunol 1981; 127: 1433–1438.PubMedGoogle Scholar
  36. 36.
    Bobbio SA, Wood ML, Monaco AP. Significant augmentation of specific unresponsiveness by rapamycin in ALS-treated, bone marrow injected mice. Transplant Sci 1993; 3: 51–55.Google Scholar
  37. 37.
    Thomas JM, Carver FM, Foil MB et al. Renal allograft tolerance induced with ATG and donor bone marrow in outbred rhesus monkeys. Transplantation 1983; 36: 104–106.PubMedGoogle Scholar
  38. 38.
    Thomas J, Carver M, Cunningham P et al. Promotion of incompatible allograft acceptance in rhesus monkeys given posttransplant antithymocyte globulin and donor bone marrow. I. In vivo parameters and immunohistologic evidence suggesting microchimerism. Transplantation 1987; 43: 332–338.PubMedGoogle Scholar
  39. 39.
    Thomas JM, Carver FM, Cunningham PR et al. Kidney allograft tolerance in primates without chronic immunosuppression—the role of veto cells. Transplantation 1991; 51: 198–207.PubMedGoogle Scholar
  40. 40.
    Thomas J, Alqaisi M, Cunningham P et al. The development of a posttransplant TLI treatment strategy that promotes organ allograft acceptance without chronic immunosuppression. Transplantation 1992; 53: 247–258.PubMedGoogle Scholar
  41. 41.
    Miller RG. The veto phenomenom and T cell regulation. Immunol Today 1986; 7: 112–114.Google Scholar
  42. 42.
    Wofsy D, Mayes DC, Woodcock J et al. Inhibition of humoral immunity in vivo by monoclonal antibody to L3T4: studies with soluble antigens in intact mice. J Immunol 1985; 135: 1698–1701.PubMedGoogle Scholar
  43. 42.
    Wolfsy D, Mayes DC, Woodcock J, Seaman EW. Inhibition of humoral immunity in vivo by monoclonal antibody to L3T4: studies with soluble antigens in intact mice. J Immunol 1985; 135: 1698–1701.Google Scholar
  44. 43.
    Goronzy J, Weyand CM, Fathman CG. Long-term humoral unresponsiveness in vivo, induced by treatment with monoclonal antibody against L3T4. J Exp Med 1986; 164: 911–925.PubMedGoogle Scholar
  45. 44.
    Benjamin RJ, Cobbold SP, Clark MR et al. Tolerance to rat monoclonal antibodies. Implications for serotherapy. J Exp Med 1986; 163: 1539–1552.PubMedGoogle Scholar
  46. 45.
    Benjamin RJ, Qin SX, Wise MP et al. Mechanisms of monoclonal antibody-facilitated tolerance induction: a possible role for the CD4 (L3T4) and CD11a (LFA-1) molecules in self-non-self discrimination. Eur J Immunol 1988; 18: 1079–1088.PubMedGoogle Scholar
  47. 46.
    Qin S, Cobbold S, Tighe H et al. CD4 monoclonal antibody pairs for immunosuppression and tolerance induction. Eur J Immunol 1987; 17: 1159–1165.PubMedGoogle Scholar
  48. 47.
    Gutstein NL, Wofsy D. Administration of F(ab’)2 fragments of monoclonal antibody to L3T4 inhibits humoral immunity in mice without depleting L3T4+ cells. J Immunol 1986; 137: 3414–3419.PubMedGoogle Scholar
  49. 48.
    Qin SX, Wise M, Cobbold SP et al. Induction of tolerance in peripheral T cells with monoclonal antibodies. Eur J Immunol 1990; 20: 2737–2745.PubMedGoogle Scholar
  50. 49.
    Hirsch R, Chatenoud L, Gress RE et al. Suppression of the humoral response to anti-CD3 monoclonal antibody. Transplantation 1989; 47: 853–857.PubMedGoogle Scholar
  51. 50.
    Qin SX, Cobbold S, Benjamin R et al. Induction of classical transplantation tolerance in the adult. J Exp Med 1989; 169: 779–794.PubMedGoogle Scholar
  52. 51.
    Qin S, Cobbold SP, Pope H et al. “Infectious” transplantation tolerance. Science 1993; 259: 974–977.PubMedGoogle Scholar
  53. 52.
    Cobbold SP, Qin SX, Waldmann H. Reprogramming the immune system for tolerance with monoclonal antibodies. Semin Immunol 1990; 2: 377–387.PubMedGoogle Scholar
  54. 53.
    Gershon RK, Kondo K. Infectious immunological tolerance. Immunology 1971; 21: 903–914.PubMedGoogle Scholar
  55. 54.
    Shizuru JA, Gregory AK, Chao CT et al. Islet allograft survival after a single course of treatment of recipient with antibody to L3T4. Science 1987; 237: 278–280.PubMedGoogle Scholar
  56. 55.
    Shizuru JA, Seydel KB, Flavin TF et al. Induction of donor-specific unresponsiveness to cardiac allografts in rats by pretransplant anti-CD4 monoclonal antibody therapy. Transplantation 1990; 50: 366–373.PubMedGoogle Scholar
  57. 56.
    Madsen JC, Peugh WN, Wood KJ et al. The effect of anti-L3T4 monoclonal antibody treatment on first-set rejection of murine cardiac allografts. Transplantation 1987; 44: 849–852.PubMedGoogle Scholar
  58. 57.
    Siegling A, Lehmann M, Riedel H et al. A nondepleting anti-rat CD4 monoclonal antibody that suppresses T helper 1-like but not T helper 2-like intragraft lymphokine secretion induces long-term survival of renal allografts. Transplantation 1994; 57: 464–467.PubMedGoogle Scholar
  59. 58.
    Pearson TC, Madsen JC, Larsen CP et al. Induction of transplantation tolerance in adults using donor antigen and anti-CD4 monoclonal antibody. Transplantation 1992; 54: 475–483.PubMedGoogle Scholar
  60. 59.
    Wood KJ. Transplantation tolerance with monoclonal antibodies. Semin Immunol 1990; 2: 389–399.PubMedGoogle Scholar
  61. 60.
    Guckel B, Berek C, Lutz M et al. Anti-CD2 antibodies induce T cell unresponsiveness in vivo. J Exp Med 1991; 174: 957–967.PubMedGoogle Scholar
  62. 61.
    Bromberg JS, Chavin KD, Altevogt P et al. Anti-CD2 monoclonal antibodies alter cell-mediated immunity in vivo. Transplantation 1991; 51: 219–225.PubMedGoogle Scholar
  63. 62.
    Jonker M, Golsdstein G, Balner H. Effects of in vivo administration of monoclonal antibodies specific for human T cell subpopulations on the immune system in a rhesus monkey model. Transplantation 1983; 35: 521–526.PubMedGoogle Scholar
  64. 63.
    Chavin KD, Qin L, Lin J et al. Combination anti-CD2 and anti-CD3 monoclonal antibodies induce tolerance while altering interleukin-2, interleukin-4, tumor necrosis factor, and transforming growth factor-beta production. Ann Surg 1993; 218: 492–501.PubMedGoogle Scholar
  65. 64.
    Nicolls MR, Aversa GG, Pearce NW et al. Induction of long-term specific tolerance to allografts in rats by therapy with an anti-CD3-like monoclonal antibody. Transplantation 1993; 55: 459–468.PubMedGoogle Scholar
  66. 65.
    Schwartz RH. A cell culture model for T lymphocyte clonal anergy. Science 1990; 248: 1349–1356.PubMedGoogle Scholar
  67. 66.
    Linsley PS, Clark EA, Ledbetter JA. T-cell antigen CD28 mediates adhesion with B cells by interacting with activation antigen B7/BB-1. Proc Natl Acad Sci USA 1990; 87: 5031–5035.PubMedGoogle Scholar
  68. 67.
    Linsley PS, Brady W, Urnes M et al. CTLA-4 is a second receptor for the B cell activation antigen B7. J Exp Med 1991; 174: 561–569.PubMedGoogle Scholar
  69. 68.
    Van Den Eertwegh AJ, Noelle RJ, Roy M et al. In vivo CD40gp39 interactions are essential for thymus-dependent humoral immunity. I. In vivo expression of CD40 ligand, cytokines, and antibody production delineates sites of cognate T-B cell interactions. J Exp Med 1993; 178: 1555–1565.PubMedGoogle Scholar
  70. 69.
    Linsley PS, Wallace PM, Johnson J et al. Immunosuppression in vivo by a soluble form of the CTLA-4 T cell activation molecule. Science 1992; 257: 792–795.PubMedGoogle Scholar
  71. 70.
    Lenschow DJ, Zeng Y, Thistlethwaite JR et al. Long-term survival of xenogeneic pancreatic islet grafts induced by CTLA41g. Science 1992; 257: 789–792.PubMedGoogle Scholar
  72. 71.
    Ferber I, SChonrich G, Schenkel J et al. Levels of peripheral T cell tolerance induced by different doses of tolerogen. Science 1994; 263: 674–676.PubMedGoogle Scholar
  73. 72.
    Schonrich G, Alferink J, Klevenz et al. Tolerance induction as a multi-step process. Eur J Immunol 1994; 24: 285–293.PubMedGoogle Scholar
  74. 73.
    Mosmann TR, Coffman RL. TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu Rev Immunol 1989; 7: 145–173.PubMedGoogle Scholar
  75. 74.
    Lombardi G, Sidhu S, Batchelor R et al. Anergic T cells as suppressor cells in vitro. Science 1994; 264: 1587–1589.PubMedGoogle Scholar
  76. 75.
    Morrison SL, Johnson MJ, Herzenberg LA et al. Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains. Proc Natl Acad Sci USA 1984; 81: 6851–6855.PubMedGoogle Scholar
  77. 76.
    Riechmann L, Clark M, Waldmann H et al. Reshaping human antibodies for therapy. Nature 1988; 332: 323–327.PubMedGoogle Scholar
  78. 77.
    Lazarovits AI, Rochon J, Banks L et al. Human mouse chimeric CD7 monoclonal antibody (SDZCHH380) for the prophylaxis of kidney transplant rejection. J Immunol 1993; 150: 5163–5174.PubMedGoogle Scholar
  79. 78.
    Isaacs JD, Watts RA, Hazleman BL et al. Humanised monoclonal antibody therapy for rheumatoid arthritis. Lancet 1992; 340: 748–752.PubMedGoogle Scholar
  80. 79.
    Elliot MJ, Maini RN, Feldmann M et al. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet 1994; 344: 1105–1110.Google Scholar
  81. 80.
    Elliot MJ, Maini RN, Feldmann M et al. Repeated therapy with monoclonal antibody to tumour necrosis factor alpha (cA2) in patients with rheumatoid arthritis. Lancet 1994; 344: 1125–1127.Google Scholar
  82. 81.
    Isaacs JD, Clark MR, Greenwood J et al. Therapy with monoclonal antibodies. An in vivo model for the assessment of therapeutic potential. J Immunol 1992; 148: 3062–3071.PubMedGoogle Scholar
  83. 82.
    Bolt S, Routledge E, Lloyd I et al. The generation of a humanized, non-mitogenic CD3 monoclonal antibody which retains in vitro immunosuppressive properties. Eur J Immunol 1993; 23: 403–411.PubMedGoogle Scholar
  84. 83.
    Chatenoud L, Bach JF. Antigenic modulation: a major mechanism of antibody action. Immunol Today 1984; 5: 20–25.Google Scholar
  85. 84.
    Van Lier RA, Boot, de Groot ER et al. Induction of T cell proliferation with anti-CD3 switch-variant monoclonal antibodies: effects of heavy chain isotype in monocyte-dependent systems. Eur J Immunol 1987; 17: 1599–1604.PubMedGoogle Scholar
  86. 85.
    Van Wauwe JP, de Mey Jr, Goossens JG. OKT3: a monoclonal anti-human T lymphocyte antibody with potent mitogenic properties. J Immunol 1980; 124: 2708–2713.PubMedGoogle Scholar
  87. 86.
    Emmrich F, Kanz L, Eichmann K. Cross-linking of the T cell receptor complex with the subset-specific differentiation antigen stimulates interleukin 2 receptor expression in human CD4 and CD8 T cells. Eur J Immunol 1987; 17: 529–534.PubMedGoogle Scholar
  88. 87.
    Chatenoud L, Ferran C, Legendre C et al. In vivo cell activation following OKT3 administration. Systemic cytokine release and modulation by corticosteroids. Transplantation 1990; 49: 697–702.PubMedGoogle Scholar
  89. 88.
    Abramowicz D, Schandene L, Goldmann M et al. Release of tumor necrosis factor, interleukin-2, and gamma-interferon in serum after injection of OKT3 monoclonal antibody in kidney transplant recipients. Transplantation 1989; 47: 606–608.PubMedGoogle Scholar
  90. 89.
    Ferran C, Dy M, Sheehan K et al. Cascade modulation by anti-tumor necrosis factor monoclonal antibody of interferon-gamma, interleukin 3 and interleukin 6 release after triggering of the CD3/T cell receptor activation pathway. Eur J Immunol 1991; 21: 2349–2353.PubMedGoogle Scholar
  91. 90.
    Chatenoud L, Legendre C, Ferran C et al. Corticosteroid inhibition of the OKT3-induced cytokine-related syndrome—dosage and kinetics prerequisites. Transplantation 1991; 51: 334–338.PubMedGoogle Scholar
  92. 91.
    Charpentier B, Hiesse C, Lantz O et al. Evidence that antihuman tumor necrosis factor monoclonal antibody prevents OKT3-induced acute syndrome. Transplantation 1992; 54: 997–1002.PubMedGoogle Scholar
  93. 92.
    Cosimi AB. Clinical development of Orthoclone OKT3. Transplant Proc 1987; 19: 7–16.PubMedGoogle Scholar
  94. 93.
    Goldstein G. Overview of the development of Orthoclone OKT3: monoclonal antibody for therapeutic use in transplantation. Transplant Proc 1987; 19: 1–6.PubMedGoogle Scholar
  95. 94.
    Parlevliet KJ, Jonker M, Ten Berge RJ et al. Anti-CD3 murine monoclonal isotype switch variants tested for toxicity and immunologic monitoring in four chimpanzees. Transplantation 1990; 50: 889–892.Google Scholar
  96. 95.
    Parlevliet KJ, Ten Berge IJ, Yong SL et al. In vivo effects of IgA and IgG2a anti-CD3 isotype switch variants. J Clin Invest 1994; 93: 2519–2525.PubMedGoogle Scholar
  97. 96.
    Hirsch R, Bluestone Ja, De Nenno L et al. Anti-CD3 F(ab’)2 fragments are immunosuppressive in vivo without evoking either the strong humoral response or morbidity associated with whole mAb. Transplantation 1990; 49: 1117–1123.PubMedGoogle Scholar
  98. 97.
    Alegre ML, Collins AM, Pulito VL et al. Effect of a single amino acid mutation on the activating and immunosuppressive properties of a “humanized” OKT3 monoclonal antibody. J Immunol 1992; 148: 3461–3468.PubMedGoogle Scholar
  99. 98.
    Chatenoud L, Baudihaye MF, Kreis H et al. Human in vivo anti-genic modulation induced by the anti-T cell OKT3 monoclonal antibody. Eur J Immunol 1982; 12: 979–982.PubMedGoogle Scholar
  100. 99.
    Meuer SC, Acuto O, Hercend T et al. The human T-cell receptor. Annu Rev Immunol 1984; 2: 23–50.PubMedGoogle Scholar
  101. 100.
    Hirsch R, Eckhaus M, Auchincloss H Jr et al. Effects of in vivo administration of anti-T3 monoclonal antibody on T cell function in mice. I. Immunosuppression of transplantation responses. J Immunol 1988; 140: 3766–3772.PubMedGoogle Scholar
  102. 101.
    Smith CA, Williams GT, Kingston R et al. Antibodies to CD3/T-cell receptor complex induce death by apoptosis in immature T cells in thymic cultures. Nature 1989; 337: 181–184.PubMedGoogle Scholar
  103. 102.
    Wesselborg S, Janssen O, Kabelitz D. Induction of activation-driven death (apoptosis) in activated but not resting peripheral blood T cells. J Immunol 1993; 150: 4338–4345.PubMedGoogle Scholar
  104. 103.
    Wong JT, Colvin RB. Selective reduction and proliferation of the CD4+ and CD8+ T cell subsets with bispecific monoclonal antibodies: evidence for inter-T cell-mediated cytolysis. Clin Immunol Immunopathol 1991; 58: 236–250.PubMedGoogle Scholar
  105. 104.
    Chatenoud L, Baudrihaye MF, Chkoff N et al. Restriction of the human in vivo immune response against the mouse monoclonal antibody OKT3. J Immunol 1986; 137: 830–838.PubMedGoogle Scholar
  106. 105.
    Vigeral P, Chkogg N, Chatenoud L et al. Prophylactic use of OKT3 monoclonal antibody in cadaver kidney recipients. Utilization of OKT3 as the sole immunosuppressive agent. Transplantation 1986; 41: 730–733.PubMedGoogle Scholar
  107. 106.
    Caillat-Zucman S, Blumenfeld N, Legendre C et al. The OKT3 immunosuppressive effect. In situ antigenic modulation of human graft-infiltrating T cells. Transplantation 1990; 49: 156–160.PubMedGoogle Scholar
  108. 107.
    Schlitt HJ, Kurrle R, Wonigeit K. T cell activation by monoclonal antibodies directed to different epitopes on the human T cell receptor/CD3 complex: evidence for two different modes of activation. Eur J Immunol 1989; 19: 1649–1655.PubMedGoogle Scholar
  109. 108.
    Land W, Hillebrand G, Illner WD et al. First clinical experience with a new TCR/CD3-monoclonal antibody (BMA 031) in kidney transplant patients. Transpl Int 1988; 1: 116–117.PubMedGoogle Scholar
  110. 109.
    Dendorfer U, Hillebrand G, Kasper C et al. Effective prevention of interstitial rejection crises in immunological high risk patients following renal transplantation: use of high doses of the new monoclonal antibody BMA 031. Transplant Proc 1990; 22: 1789–1790.PubMedGoogle Scholar
  111. 110.
    Knight RJ, Kurrle R, McClain J et al. Clinical evaluation of induction immunosuppression with a murine IgG2b monoclonal antibody (BMA 031) directed toward the human alpha/beta-T cell receptor. Transplantation 1994; 57: 1581–1588.PubMedGoogle Scholar
  112. 111.
    Chatenoud L, Ferran C, Legendre C et al. Immunological follow-up of renal allograft recipients treated with the BMA 031 (anti-TCR) monoclonal antibody. Transplant Proc 1990; 22: 1787–1788.PubMedGoogle Scholar
  113. 112.
    Chatenoud L, Legendre C, Kurrle R et al. Absence of clinical symptoms following the first injection of anti-T cell receptor monoclonal antibody (BMA 031) despite isolated TNF release. Transplantation 1993; 55: 443–445.PubMedGoogle Scholar
  114. 113.
    Waid TH, Lucas BS, Thompson JS et al. Treatment of acute cellular rejection with T10B9.1A-31 or OKT3 in renal allograft recipients. Transplantation 1992; 53: 80–86.PubMedGoogle Scholar
  115. 114.
    Clark M, Bindon C, Dyer M et al. The improved lytic function and in vivo efficacy of monovalent monoclonal CD3 antibodies. Eur J Immunol 1989; 19: 381–388.PubMedGoogle Scholar
  116. 115.
    Villemain F, Jonker M, Bach JF et al. Fine specificity of antibodies produced in rhesus monkeys following in vivo treatment with anti-T cell murine monoclonal antibodies. Eur J Immunol 1986; 16: 945–949.PubMedGoogle Scholar
  117. 116.
    Niaudet P, Jean G, Broyer M et al. Anti-OKT3 response following prophylactic treatment in paediatric kidney transplant recipients. Pediatr Nephrol 1993; 7: 263–267.PubMedGoogle Scholar
  118. 117.
    Baudihaye MF, Chatenoud L, Kreis H et al. Unusually restricted anti-isotype human immune response to OKT3 monoclonal antibody. Eur J Immunol 1984; 14: 686–691.Google Scholar
  119. 118.
    Legendre C, Kreis H, Bach JF et al. Prediction of successful allograft rejection retreatment with OKT3. Transplantation 1992; 53: 87–90.PubMedGoogle Scholar
  120. 119.
    Lockwood CM, Thiru S, Isaacs JD et al. Long-term remission of intractable systemic vasculitis with monoclonal antibody therapy. Lancet 1993; 341: 1620–1622.PubMedGoogle Scholar
  121. 120.
    Vittecoq D, Chevret S, Morand-Joubert L et al. Passive immunotherapy in AIDS: a double-blind randomized study based on transfusions of plasma rich in anti-human immunodeficiency virus I antibodies vs. transfusions of seronegative plasma. Proc Natl Acad Sci USA 1995; 92: 1195–1199.PubMedGoogle Scholar
  122. 121.
    Blanche S, Le Deist F, Veber F et al. Treatment of severe Epstein-Barr virus-induced polyclonal B-lymphocyte proliferation by anti-B-cell monoclonal antibodies. Two cases after HLA-mismatched bone marrow transplantation. Ann Intern Med 1988; 108: 199–203.PubMedGoogle Scholar
  123. 122.
    Stephan Jl, Le Deist F, Blanche S et al. Treatment of central nervous system B lymphoproliferative syndrome by local infusion of a Bcell-specific monoclonal antibody. Transplantation 1992; 54: 246–249.PubMedGoogle Scholar
  124. 123.
    Fanslow WC, Sims JE, Sassenfeld H et al. Regulation of alloreactivity in vivo by a soluble form of the interleukin-1 receptor. Science 1990; 248: 739–742.PubMedGoogle Scholar
  125. 124.
    Jacobs CA, Lynch DH, Roux ER et al. Characterization and pharmacokinetic parameters of recombinant soluble interleukin-4 receptor. Blood 1991; 77: 2396–2403.PubMedGoogle Scholar
  126. 125.
    Ozmen L, Gribaudo G, Fountoulakis M et al. Mouse soluble IFN gamma receptor as IFN gamma inhibitor. Distribution, antigenicity, and activity after injection in mice. J Immunol 1993; 150: 2698–2705.PubMedGoogle Scholar
  127. 126.
    Dinarello CA, Thompson RC. Blocking IL-1: interleukin 1 receptor antagonist in vivo and in vitro. Immunol Today 1991; 12: 404–410.PubMedGoogle Scholar
  128. 127.
    Peppel K, Crawford D, Beutler B. A tumor necrosis factor (TNF) receptor-IgG heavy chain chimeric protein as a bivalent antagonist of TNF activity. J Exp Med 1991; 174: 1483–1489.PubMedGoogle Scholar
  129. 128.
    Lesslauer W. Tabuchi H, Gentz R et al. Recombinant soluble tumor necrosis factor receptor proteins protect mice from lipopolysaccharide-induced lethality. Eur J Immunol 1991; 21: 2883–2886.PubMedGoogle Scholar
  130. 129.
    May LT, Neta R, Moldawer LL et al. Antibodies chaperone circulating IL-6. Paradoxical effects of anti-IL-6 “neutralizing” antibodies in vivo. J Immunol 1993; 151: 3225–3236.PubMedGoogle Scholar
  131. 130.
    Jones AT, Ziltener HJ. Enhancement of the biologic effects of interleukin-3 in vivo by anti-interleukin-3 antibodies. Blood 1993; 82: 1133–1141.PubMedGoogle Scholar
  132. 131.
    Finkelman FD, Madden KB, Morris SC et al. Anti-cytokine antibodies as carrier proteins. Prolongation of in vivo effects of exogenous cytokines by injection of cytokine-anti-cytokine antibody complexes. J Immunol 1993; 151: 1235–1244.PubMedGoogle Scholar
  133. 132.
    Klein B, Wijdenes J, Zhang XG et al. Murine anti-interleukin-6 monoclonal antibody therapy for a patient with plasma cell leukemia. Blood 1991; 78: 1198–1204.PubMedGoogle Scholar
  134. 133.
    Dinarello CA. Anti-cytokine strategies. Eur Cytokine Netw 1992; 3: 7–17.PubMedGoogle Scholar
  135. 134.
    Bach JF. Anti-gamma interferon (IFN-gamma) monoclonal antibodies. In: Monoclonal Antibodies and Peptide Therapy in Autoimmune Diseases, BACH JF (Ed.) 1993; 319-391.Google Scholar
  136. 135.
    Imaga DK, Millis JM, Olthoff et al. The role of tumor necrosis factor in allograft rejection. II. Evidence that antibody therapy against tumor necrosis factor-alpha and lymphotoxin enhances cardiac allograft survival in rats. Transplantation 1990; 50: 189–193.Google Scholar
  137. 136.
    Imaga DK, Millis JM, Seu P et al. The role of tumor necrosis factor in allograft rejection. III. Evidence that anti-TNF antibody therapy prolongs allograft survival in rats with acute rejection. Transplantation 1991; 51: 57–62.Google Scholar
  138. 137.
    Nicolas JF, Chamchick N, Thivolet J et al. CD4 antibody treatment of severe psoriasis. Lancet 1991; 338: 321.PubMedGoogle Scholar
  139. 138.
    Prinz J, Braun-Falco O, Meurer M et al. Chimaeric CD4 monoclonal antibody in treatment of generalised pustular psoriasis. Lancet 1991; 338: 320–321.PubMedGoogle Scholar
  140. 139.
    Riethmuller G, Schneider-Gadicke E, Schlimok G et al. Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes’ C colorectal carcinoma. German Cancer Aid 17-1A Study Group. Lancet 1994; 343: 1177–1183.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 1995

Authors and Affiliations

  • Lucienne Chatenoud
  • Michelle Webb
  • Jean-François Bach

There are no affiliations available

Personalised recommendations